Akshay Sood
Overview
Explore the profile of Akshay Sood including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
320
Citations
5046
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sood V, Rishel Brakey H, Myers O, Shore X, Sood A
JMIR Form Res
. 2025 Mar;
9:e67999.
PMID: 40080056
Background: Pneumoconiosis prevalence is increasing in the United States, especially among coal miners. Contemporaneously with an increased need for specialized multidisciplinary care for miners, there is a shortage of experts...
2.
Vigano S, Finati M, Stephens A, Bertini A, Finocchiaro A, Lughezzani G, et al.
Prostate
. 2025 Mar;
:e24882.
PMID: 40066656
Background: Socioeconomic status and geographical location contribute to disparities in localized prostate cancer (PCa) treatment. We examined the impact of area of deprivation index (ADI) on initial treatment type for...
3.
Sood A, Cotton Jarrell W, Shore X, Sosa N, Parada A, Edwardson N, et al.
JMIR Public Health Surveill
. 2025 Jan;
11:e59845.
PMID: 39869851
Background: Numerous studies have assessed the risk of SARS-CoV-2 exposure and infection among health care workers during the pandemic. However, far fewer studies have investigated the impact of SARS-CoV-2 on...
4.
Cirulli G, Stephens A, Chiarelli G, Finati M, Bertini A, Chase M, et al.
Prostate
. 2025 Jan;
e24856.
PMID: 39869547
Introduction: PSA screening remains a pivotal tool for early prostate cancer (PCa) detection. International guidelines rely on evidence from three major randomized clinical trials: ERSPC, PLCO, and CAP. We aim...
5.
Gleasner R, Sood A
Learn Publ
. 2024 Dec;
38(1).
PMID: 39734329
This paper aims to enhance the understanding of the role of special issues in the evolving landscape of academic publishing, offering insights for publishers, editors, guest editors, and researchers, including...
6.
Chiarelli G, Davis M, Stephens A, Finati M, Cirulli G, Morrison C, et al.
Prostate
. 2024 Dec;
85(4):354-363.
PMID: 39651707
Background: Previous studies found that Midlife Baseline PSA (MB PSA) predicts the risk of developing lethal prostate cancer (PCa), although the cohorts were homogenous in terms of racial compositions. We...
7.
Dason S, Goradia R, Heh V, Sood A, Lee M, Son Y, et al.
Clin Genitourin Cancer
. 2024 Nov;
23(1):102258.
PMID: 39615117
Introduction: Management of metastatic renal cell carcinoma (mRCC) is highly individualized and often involves cytoreductive nephrectomy (CN) and systemic therapy (ST). The optimal sequencing of CN and ST is uncertain....
8.
Chiarelli G, Stephens A, Finati M, Cirulli G, Tinsley S, Wang Y, et al.
World J Urol
. 2024 Nov;
42(1):646.
PMID: 39589591
Purpose: To assess active surveillance (AS) adherence for prostate cancer (PCa) in a "real-world" clinical practice. Materials And Methods: We utilized our institutional database which was built by interrogating electronic...
9.
Stephens A, Morrison C, Lutchka J, Richard C, Hares K, Tinsley S, et al.
Urology
. 2024 Nov;
197:80-87.
PMID: 39580118
Objective: To examine the frequency and rate at which transfeminine patients receive prostate-specific antigen testing compared to a matched cisgender cohort. Methods: Patients with prostates who had encounters in our...
10.
Finati M, Stephens A, Cirulli G, Chiarelli G, Tinsley S, Morrison C, et al.
JNCI Cancer Spectr
. 2024 Nov;
8(6).
PMID: 39576690
Background: Socioeconomic and demographic factors contribute to disparity in prostate cancer (PCa) outcomes. We examined the impact of Area of Deprivation Index (ADI) and race on PCa incidence and lethality...